Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
复制标题
血液学恶性肿瘤和COVID-19患者的临床特征和结果表明，延长SARS-COV-2运输是一个重要问题。
DOI：
10.1007/s00277-021-04656-z
复制
发表时间：
2021-11
影响因子：
3.5
通讯作者：
Kaplanski G
中科院分区：
文献类型：
--
作者：
Arcani R;Colle J;Cauchois R;Koubi M;Jarrot PA;Jean R;Boyer A;Lachamp J;Tichadou A;Couderc AL;Farnault L;Costello R;Venton G;Kaplanski G
血液系统恶性肿瘤患者的COVID-19病程特异性研究仍然很少。因此，我们的目的是比较血液系统恶性肿瘤患者与非恶性肿瘤患者，按性别和年龄匹配，并在同一时间和同一中心因COVID-19住院。在25例恶性血液病患者中，我们发现死亡率（40%对4%，p < 0.01），RT-PCR阳性天数（21.2 ± 15.9天[范围，3-57]对比7.4 ± 5.6天[范围，1-24]，p < 0.01），最大病毒载量（平均最小Ct，17.2 ± 5.2 [范围，10-30]对比26.5 ± 5.1 [范围，15-33]，p < 0.0001）和症状发作与临床恶化之间的延迟（症状发作与吸入氧分数最大需求第一天之间的平均持续时间，14.3 ± 10.7天vs 9.6 ± 3.7天，p = 0.0485）高于其他患者。血液系统恶性肿瘤患者的COVID-19病程具有延迟性，并且更严重，死亡率更高，患者可能被视为超级传播者。临床医生和重症监护医生需要接受培训，以了解血液系统恶性肿瘤患者的COVID-19病程的特异性。在线版本包含补充材料，可通过10.1007/s 00277 -021-04656-z获得。
Specificities of COVID-19 disease course in patients with haematologic malignancies are still poorly studied. So, we aimed to compare patients with haematologic malignancies to patients without malignancies, matched by sex and age and hospitalised for COVID-19 at the same time and in the same centre. Among 25 patients with haematologic malignancies, we found that mortality (40% versus 4%, p < 0.01), number of days with RT-PCR positivity (21.2 ± 15.9 days [range, 3–57] versus 7.4 ± 5.6 days [range, 1–24], p < 0.01), maximal viral load (mean minimal Ct, 17.2 ± 5.2 [range, 10–30] versus 26.5 ± 5.1 [range, 15–33], p < 0.0001) and the delay between symptom onset and clinical worsening (mean time duration between symptom onset and first day of maximum requirement in inspired oxygen fraction, 14.3 ± 10.7 days versus 9.6 ± 3.7 days, p = 0.0485) were higher than in other patients. COVID-19 course in patients with haematologic malignancies has a delayed onset and is more severe with a higher mortality, and patients may be considered as super-spreaders. Clinicians and intensivists need to be trained to understand the specificity of COVID-19 courses in patients with haematological malignancies. The online version contains supplementary material available at 10.1007/s00277-021-04656-z.
登录
查看更多内容
影响因子：
24.7
作者：
Passamonti, Francesco;Cattaneo, Chiara;Corradini, Paolo
通讯作者：
Corradini, Paolo
血液学恶性肿瘤和共同19岁的患者的结局：3377例患者的系统评价和荟萃分析。
影响因子：
20.3
作者：
Vijenthira A;Gong IY;Fox TA;Booth S;Cook G;Fattizzo B;Martín-Moro F;Razanamahery J;Riches JC;Zwicker J;Patell R;Vekemans MC;Scarfò L;Chatzikonstantinou T;Yildiz H;Lattenist R;Mantzaris I;Wood WA;Hicks LK
通讯作者：
Hicks LK
SARS-CoV-2 和 COVID-19 的特征
DOI：
10.1038/s41579-020-00459-7
发表时间：
2021-03
期刊：
Nature reviews. Microbiology
影响因子：
--
作者：
Hu B;Guo H;Zhou P;Shi ZL
通讯作者：
Shi ZL
影响因子：
6.2
作者：
Cattaneo, Chiara;Daffini, Rosa;Rossi, Giuseppe
通讯作者：
Rossi, Giuseppe
影响因子：
3.5
作者：
Manrubia, SC;Escarmís, C;Lázaro, E
通讯作者：
Lázaro, E